When the Living Drug Strikes Back: Cytokine Release Syndrome and Neurotoxicity from CAR T-Cell and Bispecific Therapies
Chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers have produced durable remissions in haematological malignancies that were previously considered refractory, and the bispecific class has now extended this approach to a solid tumour, extensive-stage small-cell lung cancer, through the delta-like ligand 3 engager tarlatamab. The shared mechanism of intense, sustained...